Quick Evidence Summary
| Evidence type | Current status |
|---|---|
| Pilot human study | Small phase-I pharmacology study (Dorr et al., 1996) |
| Larger controlled human trials | None of Melanotan-2 itself |
| FDA-approved descendant | Bremelanotide (Vyleesi) - went through full trial program |
| Safety signal | Case reports of mole changes and melanoma |
| Regulatory status | Not FDA-approved; sold as a research chemical |
What Melanotan-2 Is
Melanotan-2 is a synthetic analogue of alpha-MSH that broadly activates melanocortin receptors, including MC1R (melanocyte/tanning) and MC4R (appetite and sexual arousal pathways), which is why it's historically been associated with tanning, appetite suppression, and libido effects all at once. That broad receptor activity, hitting multiple melanocortin receptors rather than one selectively, is also the basis for the safety concerns described below.
The Original Pilot Study, and What Came After
The foundational human data on Melanotan-2 comes from an early pilot phase-I clinical study in a small number of male volunteers, Dorr et al. (1996), which used escalating doses from roughly 0.01 to 0.03 mg/kg body weight, dosed daily on a Monday-through-Friday schedule. That study established the tanning, appetite-suppressing, and libido-related pharmacology, along with an initial dose range, but it was a small pilot pharmacology study, not a large randomized efficacy trial.
Beyond that early work, most of the available human evidence on Melanotan-2 specifically is observational or case-report level, documenting both intended effects and the mole and melanoma-related adverse events described below, rather than large randomized controlled trials. Research-community loading and maintenance dosing conventions descend from that early pharmacology work combined with years of informal use-pattern reporting, not from a completed controlled dosing trial.
Why Its Descendant Compound Has Full FDA Approval and Melanotan-2 Doesn't
PT-141 (bremelanotide) was developed from Melanotan-2 by modifying it to act more selectively on the MC4R receptor associated with sexual arousal, reducing the tanning and off-target effects that come with Melanotan-2's broader receptor activity. Bremelanotide went through a full FDA clinical trial program and was approved as Vyleesi, for one narrow indication in premenopausal women with hypoactive sexual desire disorder. Melanotan-2 itself was never put through that pipeline and has no approval of its own.
Why this matters: a related, FDA-approved compound existing doesn't transfer evidentiary weight to Melanotan-2. The two molecules act on overlapping but not identical receptor profiles, and only one of them has been through a controlled trial program and regulatory review.
Evidence Gaps and Regulatory Status
Melanotan-2 is not FDA-approved for tanning, appetite suppression, libido, or any other indication, and it is not currently listed on the FDA's 503A or 503B bulk drug substance lists for compounding pharmacies. Products sold as Melanotan-2 or MT-2 are marketed as research chemicals for laboratory research use only, not for human consumption. Multiple international regulators, including agencies in the UK and Australia, have separately issued public warnings over the years about Melanotan products sold illegally as tanning injections outside any regulated supply chain. Case reports have linked Melanotan-2 use to new or changing moles and, in some reported cases, melanoma, a safety signal consistent with its broad, non-selective melanocortin receptor activity. Purchasing a product labeled "research use only" carries no assurance of purity, accurate dosing, or safety evaluation by any regulator.
Bloodwork to Track
There's no Melanotan-2-specific blood marker, but given the mole-related safety signal, regular dermatological skin checks are a more relevant monitoring step than bloodwork alone. See the peptide bloodwork guide for what a general baseline panel typically includes.
Related Reading
For research dosing conventions and the full safety breakdown, see the Melanotan-2 reference page. For how it compares to a related MC4R-focused peptide, see the PT-141 evidence review. BioStackIQ's Rate My Stack can help you think through where a compound like this fits into a broader stack, with this evidence picture in mind.